

WEST Search History

DATE: Thursday, April 17, 2003

<u>Set Name</u>	<u>Query</u>	<u>Hit Count</u>	<u>Set Name</u>
side by side		result set	
<i>DB=USPT,PGPB,JPAB,EPAB,DWPI; PLUR=YES; OP=ADJ</i>			
L124	L112 and L123	1	L124
L123	L106 and L122	432	L123
L122	L121 and L87	617	L122
L121	psoriasis	25598	L121
L120	L115 and L119	0	L120
L119	streptomyces near5 fermentation product	3	L119
L118	L94 and L116	2	L118
L117	L95 and L116	0	L117
L116	L112 and L115	11	L116
L115	(Peripheral benzodiazepine receptor) near5 (agonist or RO5-4864 or benzodiazepine)	85	L115
L114	L108 and L110	1	L114
L113	L104 and L110	2	L113
L112	L111	11	L112
L111	L103 and L110	11	L111
L110	topical near5 composition	18458	L110
L109	L104 and L108	1	L109
L108	L103 and L107	5	L108
L107	L87 and L106	1659	L107
L106	treat or cure or ameliorate pr prevent	734129	L106
L105	L95 and L103	0	L105
L104	L94 and L103	3	L104
L103	(Peripheral benzodiazepine receptor) near5 (binding compounds or benzodiazepine)	85	L103
L102	L87 and L100	1	L102
L101	L87 and L99	0	L101
L100	L97 and L85	204	L100
L99	L95 and L96	6	L99
L98	L97	264	L98
L97	L94 and L96	264	L97
L96	benzodiazepine	8657	L96
L95	Nocardia	3668	L95
L94	Streptomyces or actinomycete	23092	L94

L93	L87 and L8		1	L93
L92	L87 and L91		1	L92
L91	L89 and L90		211	L91
L90	L83 and L85		12043	L90
L89	L80 and L83		287	L89
L88	(cutaneous or skin or derm or scalp) near5 stress		2124	L88
L87	(cutaneous or skin or derm or scalp) same stress		6913	L87
L86	(cutaneous or skin or derm or scalp) with stress		3986	L86
L85	(composition or produc\$9) near5 (ferment\$6 or fermentation or culture or growth)		112054	L85
L84	actinosinnema		0	L84
L83	streptomyces or Nocardia or actinomyces or actinomycete or filamentous bacteria		26971	L83
L82	streptomyces or Nocardia or actinomyces or filamentous bacteria		25339	L82
L81	streptomyces or Ncardia or actinomyces or filamentous bacteria		23284	L81
L80	benzodiazepin\$6		9433	L80
L79	benzo diazepin\$6		519	L79
<i>DB=USPT,PGPB; PLUR=YES; OP=ADJ</i>				
L78	L69 and L60		0	L78
L77	L70 and L60		0	L77
L76	L73 and L60		0	L76
L75	L72 and L60		0	L75
L74	L72 and L73		0	L74
L73	L70 and L69		5	L73
L72	L36 and L69		35	L72
L71	L36 and L70		0	L71
L70	(PBR OR peripheral Benzopiradine receptor) near5 ligand		5	L70
L69	benzodiazepine		5543	L69
L68	L42 and L60		0	L68
L67	L28 and L60		0	L67
L66	L29 and L60		0	L66
L65	L30 and L60		0	L65
L64	L31 and L60		0	L64
L63	L33 and L60		0	L63
L62	L34 and L60		1	L62
L61	L52 and L60		0	L61
L60	US-4011140-\$ did.		1	L60
L59	L51 and L53		0	L59
L58	L50 and L53		0	L58
L57	L49 and L53		2	L57

L56	L48 and L55	1	L56
L55	L47 and L53	0	L55
L54	L52 and L53	0	L54
L53	L32 and L42	5	L53
L52	L50 and L51	24	L52
L51	L48 and L49	1344	L51
L50	L47 and L49	242	L50
L49	L30 and L31	15366	L49
L48	L30 and L33	2184	L48
L47	L31 and L36	3930	L47
L46	L40 and L41	0	L46
L45	L40 and L42	0	L45
L44	L40 and L43	0	L44
L43	L41 and L42	5	L43
L42	cutaneous stress	9	L42
L41	L29 and L32	663	L41
L40	L36 and L39	22	L40
L39	L33 and L38	969	L39
L38	L31 and L37	6455	L38
L37	L28 and L30	14144	L37
L36	L34 and L35	5885	L36
L35	((fermentatiion or culture or growth) near5 product or composaiton)	13993	L35
L34	(Nocardia or actinomycete or streptomyces or actinosinnema or filamentous bacteria or microorganism)	70601	L34
L33	retinoid or retinic acid or retinol or retinol ester	5198	L33
L32	treat or cure or protect or regenerate or recover	639902	L32
L31	((PBR OR peripheral Benzopiradine receptor) near5 ligand or bind\$9 or cling\$5 or attach\$8)	1576035	L31
L30	composition near5 (dermatol\$7 or skin or cutaneu\$6 or sun screen or cosmetic or topical)	27178	L30
L29	stress near5 (skin or derm or dermat\$9)	1556	L29
L28	Cosmetic	46241	L28

DB=USPT; PLUR=YES; OP=ADJ

L27	sun screen	1796	L27
L26	L23 and L25	0	L26
L25	L19 and L21	5	L25
L24	L10 and L11	0	L24
L23	L10 and L12	4	L23
L22	L10 and L13	1	L22
L21	L10 and L15	45	L21

L20	L11 and L19	0	L20
L19	L10 and L14	20	L19
L18	L10 and L17	0	L18
L17	L9 and L16	5	L17
L16	L8 and L15	11	L16
L15	435/886	1198	L15
L14	435/803	751	L14
L13	435/253.2	77	L13
L12	435/252.35	324	L12
L11	435/251.1	9	L11
L10	435/244	965	L10
L9	435/119	814	L9
L8	435/41	1022	L8
L7	L3 and L6	41	L7
L6	L2 and L5	70	L6
L5	L1 and L4	849	L5
L4	((424/401)!.CCLS.))	4022	L4
L3	((424/78.03)!.CCLS.))	623	L3
L2	((424/78.02)!.CCLS.))	551	L2
L1	((424/59)!.CCLS.)	2061	L1

END OF SEARCH HISTORY

Case Creation Option

Case "09831720" already exists. Please overwrite it or cancel the operation.

The Contents of Case "09831720"

Qnum	Query	DB Name	Thesaurus	Operator	Plural
Q1	((424/59)!CCLS.)	USPT	None	ADJ	YES
Q2	(((424/78.02)!CCLS.))	USPT	None	ADJ	YES
Q3	(((424/78.03)!CCLS.))	USPT	None	ADJ	YES
Q4	(((424/401)!CCLS.))	USPT	None	ADJ	YES
Q5	Q1 and Q4	USPT	None	ADJ	YES
Q6	Q2 and Q5	USPT	None	ADJ	YES
Q7	Q3 and Q6	USPT	None	ADJ	YES
Q8	435/41	USPT	None	ADJ	YES
Q9	435/119	USPT	None	ADJ	YES
Q10	435/244	USPT	None	ADJ	YES
Q11	435/251.1	USPT	None	ADJ	YES
Q12	435/252.35	USPT	None	ADJ	YES
Q13	435/253.2	USPT	None	ADJ	YES
Q14	435/803	USPT	None	ADJ	YES
Q15	435/886	USPT	None	ADJ	YES
Q16	Q8 and Q15	USPT	None	ADJ	YES
Q17	Q9 and Q16	USPT	None	ADJ	YES
Q18	Q10 and Q17	USPT	None	ADJ	YES
Q19	Q10 and Q14	USPT	None	ADJ	YES
Q20	Q11 and Q19	USPT	None	ADJ	YES
Q21	Q10 and Q15	USPT	None	ADJ	YES
Q22	Q10 and Q13	USPT	None	ADJ	YES
Q23	Q10 and Q12	USPT	None	ADJ	YES
Q24	Q10 and Q11	USPT	None	ADJ	YES

Q25	Q19 and Q21	USPT	None	ADJ	YES
Q26	Q23 and Q25	USPT	None	ADJ	YES
Q27	sun screen	USPT	None	ADJ	YES
Q28	Cosmetic	USPT,PGPB	None	ADJ	YES
Q29	stress near\$5 (skin or derm or dermat\$9)	USPT,PGPB	None	ADJ	YES
Q30	composition near\$5 (dermatol\$7 or skin or cutaneu\$6 or sun screen or cosmetic or topical)	USPT,PGPB	None	ADJ	YES
Q31	((PBR OR peripheral Benzopiradine-receptor) near\$5 ligand or bind\$9 or cling\$5 or attach\$8)	USPT,PGPB	None	ADJ	YES
Q32	treat or cure or protect or regenerate or recover	USPT,PGPB	None	ADJ	YES
Q33	retinoid or retinic acid or retinol or retinol ester	USPT,PGPB	None	ADJ	YES
Q34	(Nocardia or actinomycete or streptomyces or actinosinnema or filamentous bacteria or microorganism)	USPT,PGPB	None	ADJ	YES
Q35	((fermentation or culture or growth) near\$5 product or composition)	USPT,PGPB	None	ADJ	YES
Q36	Q34 and Q35	USPT,PGPB	None	ADJ	YES
Q37	Q28 and Q30	USPT,PGPB	None	ADJ	YES
Q38	Q31 and Q37	USPT,PGPB	None	ADJ	YES
Q39	Q33 and Q38	USPT,PGPB	None	ADJ	YES
Q40	Q36 and Q39	USPT,PGPB	None	ADJ	YES
Q41	Q29 and Q32	USPT,PGPB	None	ADJ	YES
Q42	cutaneous stress	USPT,PGPB	None	ADJ	YES
Q43	Q41 and Q42	USPT,PGPB	None	ADJ	YES
Q44	Q40 and Q43	USPT,PGPB	None	ADJ	YES
Q45	Q40 and Q42	USPT,PGPB	None	ADJ	YES
Q46	Q40 and Q41	USPT,PGPB	None	ADJ	YES

Q47	Q31 and Q6	USPT,PGPB	None	ADJ	YES
Q48	Q30 and Q33	USPT,PGPB	None	ADJ	YES
Q49	Q30 and Q31	USPT,PGPB	None	ADJ	YES
Q50	Q47 and Q49	USPT,PGPB	None	ADJ	YES
Q51	Q48 and Q49	USPT,PGPB	None	ADJ	YES
Q52	Q50 and Q51	USPT,PGPB	None	ADJ	YES
Q53	Q32 and Q42	USPT,PGPB	None	ADJ	YES
Q54	Q52 and Q53	USPT,PGPB	None	ADJ	YES
Q55	Q47 and Q53	USPT,PGPB	None	ADJ	YES
Q56	Q48 and Q53	USPT,PGPB	None	ADJ	YES
Q57	Q49 and Q53	USPT,PGPB	None	ADJ	YES
Q58	Q50 and Q53	USPT,PGPB	None	ADJ	YES
Q59	Q51 and Q53	USPT,PGPB	None	ADJ	YES
Q60	US-4011140-\$ did.	USPT,PGPB	None	ADJ	YES
Q61	Q52 and Q60	USPT,PGPB	None	ADJ	YES
Q62	Q34 and Q60	USPT,PGPB	None	ADJ	YES
Q63	Q33 and Q60	USPT,PGPB	None	ADJ	YES
Q64	Q31 and Q60	USPT,PGPB	None	ADJ	YES
Q65	Q30 and Q60	USPT,PGPB	None	ADJ	YES
Q66	Q29 and Q60	USPT,PGPB	None	ADJ	YES
Q67	Q28 and Q60	USPT,PGPB	None	ADJ	YES
Q68	Q42 and Q60	USPT,PGPB	None	ADJ	YES
Q69	benzodiazepine	USPT,PGPB	None	ADJ	YES
Q70	(PBR OR peripheral Benzopiradine receptor) near 5 ligand	USPT,PGPB	None	ADJ	YES
Q71	Q36 and Q70	USPT,PGPB	None	ADJ	YES
Q72	Q36 and Q69	USPT,PGPB	None	ADJ	YES
Q73	Q70 and Q69	USPT,PGPB	None	ADJ	YES
Q74	Q72 and Q73	USPT,PGPB	None	ADJ	YES
Q75	Q72 and Q60	USPT,PGPB	None	ADJ	YES
Q76	Q73 and Q60	USPT,PGPB	None	ADJ	YES
Q77	Q70 and Q60	USPT,PGPB	None	ADJ	YES
Q78	Q69 and Q60	USPT,PGPB	None	ADJ	YES

Q79	benzo diazepin\$6	USPT,PGPB,JPAB,EPAB,DWPI	None	ADJ	YES
Q80	benzodiazepin\$6	USPT,PGPB,JPAB,EPAB,DWPI	None	ADJ	YES
Q81	streptomyces or Nocardia or actinomyces or filamentous bacteria	USPT,PGPB,JPAB,EPAB,DWPI	None	ADJ	YES
Q82	streptomyces or Nocardia or actinomyces or filamentous bacteria	USPT,PGPB,JPAB,EPAB,DWPI	None	ADJ	YES
Q83	streptomyces or Nocardia or actinomyces or actinomycete or filamentous bacteria	USPT,PGPB,JPAB,EPAB,DWPI	None	ADJ	YES
Q84	actinosinnema	USPT,PGPB,JPAB,EPAB,DWPI	None	ADJ	YES
Q85	(composition or produc\$9) near5 (ferment\$6 or fermentation or culture or growth)	USPT,PGPB,JPAB,EPAB,DWPI	None	ADJ	YES
Q86	(cutaneous or skin or derm or scalp) with stress	USPT,PGPB,JPAB,EPAB,DWPI	None	ADJ	YES
Q87	(cutaneous or skin or derm or scalp) same stress	USPT,PGPB,JPAB,EPAB,DWPI	None	ADJ	YES
Q88	(cutaneous or skin or derm or scalp) near5 stress	USPT,PGPB,JPAB,EPAB,DWPI	None	ADJ	YES
Q89	Q80 and Q83	USPT,PGPB,JPAB,EPAB,DWPI	None	ADJ	YES
Q90	Q83 and Q85	USPT,PGPB,JPAB,EPAB,DWPI	None	ADJ	YES
Q91	Q89 and Q90	USPT,PGPB,JPAB,EPAB,DWPI	None	ADJ	YES
Q92	Q87 and Q91	USPT,PGPB,JPAB,EPAB,DWPI	None	ADJ	YES
Q93	Q87 and Q89	USPT,PGPB,JPAB,EPAB,DWPI	None	ADJ	YES
Q94	Streptomyces or actinomycete	USPT,PGPB,JPAB,EPAB,DWPI	None	ADJ	YES
Q95	Nocardia	USPT,PGPB,JPAB,EPAB,DWPI	None	ADJ	YES
Q96	benzodiazepine	USPT,PGPB,JPAB,EPAB,DWPI	None	ADJ	YES
Q97	Q94 and Q96	USPT,PGPB,JPAB,EPAB,DWPI	None	ADJ	YES
Q98	Q97	USPT,PGPB,JPAB,EPAB,DWPI	None	ADJ	YES
Q99	Q95 and Q96	USPT,PGPB,JPAB,EPAB,DWPI	None	ADJ	YES

Q100	Q97 and Q85	USPT,PGPB,JPAB,EPAB,DWPI	None	ADJ	YES
Q101	Q87 and Q99	USPT,PGPB,JPAB,EPAB,DWPI	None	ADJ	YES
Q102	Q87 and Q100	USPT,PGPB,JPAB,EPAB,DWPI	None	ADJ	YES
Q103	(Peripheral benzodiazepine receptor) near5 (binding compounds or benzodiazepine)	USPT,PGPB,JPAB,EPAB,DWPI	None	ADJ	YES
Q104	Q94 and Q103	USPT,PGPB,JPAB,EPAB,DWPI	None	ADJ	YES
Q105	Q95 and Q103	USPT,PGPB,JPAB,EPAB,DWPI	None	ADJ	YES
Q106	treat or cure or ameliorate pr prevent	USPT,PGPB,JPAB,EPAB,DWPI	None	ADJ	YES
Q107	Q87 and Q106	USPT,PGPB,JPAB,EPAB,DWPI	None	ADJ	YES
Q108	Q103 and Q107	USPT,PGPB,JPAB,EPAB,DWPI	None	ADJ	YES
Q109	Q104 and Q108	USPT,PGPB,JPAB,EPAB,DWPI	None	ADJ	YES
Q110	topical near5 composition	USPT,PGPB,JPAB,EPAB,DWPI	None	ADJ	YES
Q111	Q103 and Q110	USPT,PGPB,JPAB,EPAB,DWPI	None	ADJ	YES
Q112	Q111	USPT,PGPB,JPAB,EPAB,DWPI	None	ADJ	YES
Q113	Q104 and Q110	USPT,PGPB,JPAB,EPAB,DWPI	None	ADJ	YES
Q114	Q108 and Q110	USPT,PGPB,JPAB,EPAB,DWPI	None	ADJ	YES
Q115	(Peripheral benzodiazepine receptor) near5 (agonist or RO5-4864 or benzodiazepine)	USPT,PGPB,JPAB,EPAB,DWPI	None	ADJ	YES
Q116	Q112 and Q115	USPT,PGPB,JPAB,EPAB,DWPI	None	ADJ	YES
Q117	Q95 and Q116	USPT,PGPB,JPAB,EPAB,DWPI	None	ADJ	YES
Q118	Q94 and Q116	USPT,PGPB,JPAB,EPAB,DWPI	None	ADJ	YES
Q119	streptomyces near5 fermentation product	USPT,PGPB,JPAB,EPAB,DWPI	None	ADJ	YES
Q120	Q115 and Q119	USPT,PGPB,JPAB,EPAB,DWPI	None	ADJ	YES
Q121	psoriasis	USPT,PGPB,JPAB,EPAB,DWPI	None	ADJ	YES
Q122	Q121 and Q87	USPT,PGPB,JPAB,EPAB,DWPI	None	ADJ	YES
Q123	Q106 and Q122	USPT,PGPB,JPAB,EPAB,DWPI	None	ADJ	YES
Q124	Q112 and Q123	USPT,PGPB,JPAB,EPAB,DWPI	None	ADJ	YES

=> e ro 5 734

E1 1 RO 5-4650/CN
E2 1 RO 5-4781/CN
E3 1 --> RO 5-4864/CN
E4 1 RO 5-4933/CN
E5 1 RO 5-4964/CN
E6 1 RO 5-5115/CN
E7 1 RO 5-5119/CN
E8 1 RO 5-5120/CN
E9 1 RO 5-5122/CN
E10 1 RO 5-5340/CN
E11 1 RO 5-5345/CN
E12 1 RO 5-5354/CN

=> e benzodiazepine/cn

E1 1 BENZODIAZEPINE RECEPTOR (HUMAN CLONE MGC:1184 IMAGE:2989070)/CN
E2 1 BENZODIAZEPIN RECEPTOR RELATED PROTEIN (HUMAN CLONE CG96650-01 SEQUENCE HOMOLOG)/CN
E3 1 --> BENZODIAZEPINE/CN
E4 1 BENZODIAZEPINE BINDING INHIBITOR/CN
E5 1 BENZODIAZEPINE INHIBITING PEPTIDE/CN
E6 1 BENZODIAZEPINE KETOREDUCTASE/CN
E7 2 BENZODIAZEPINE RECEPTOR (HUMAN BREAST TUMOR-ASSOCIATED FRAGMENT)/CN
E8 2 BENZODIAZEPINE RECEPTOR (HUMAN CLONE P-HPBS11)/CN
E9 1 BENZODIAZEPINE RECEPTOR (MOUSE LEYDIG TUMOR CELL LINE MA-10 PERIPHERAL-TYPE 18,000-MOL.-WT. SUBUNIT)/CN
E10 1 BENZODIAZEPINE RECEPTOR (SCHIZOSACCHAROMYCES POMBE CLONE C72 5 GENE SPBC725.10)/CN
E11 1 BENZODIAZEPINE RECEPTOR TSPO (HELIOBACILLUS MOBILIS CLONE PH M6 GENE TSPO)/CN
E12 1 BENZODIAZEPINE RECEPTOR TSPO (METHANOSARCINA ACETIVORANS STRAIN C2A GENE MA4214)/CN

=> E3

L1 1 BENZODIAZEPINE/CN

=> e3

L2 1 "RO 5-4864"/CN

L3 734 L1 AND L2

L4 0 SKIN(L) STRESS AND L3

L5 0 L3 AND (SKIN (L) TREAT)

L6 6242 L1

L7 496 L2

L8 282 L1 AND L2

L9 0 TOPICAL COMPOSITION AND L8

INDEX 'ADISCTI, ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, AQUASCI, BIOBUSINESS, BIOCOMMERCE, BIOSIS, BIOTECHABS, BIOTECHDS, BIOTECHNO, CABA, CANCERLIT, CAPLUS, CEABA-VTB, CEN, CIN, CONFSCI, CROPB, CROPU, DDFB, DDFU, DGENE, DRUGB, DRUGLAUNCH, DRUGMONOG2, ...' ENTERED AT 14:22:05 ON 17 APR 2003

1 FILES HAVE ONE OR MORE ANSWERS
L14 QUE L12 AND SKIN STRESS

0 FILES HAVE ONE OR MORE ANSWERS
L15 QUE L13 AND SKIN STRESS

0 FILES HAVE ONE OR MORE ANSWERS
L16 QUE L13 AND L14

1 FILES HAVE ONE OR MORE ANSWERS
L17 QUE L12 AND SKIN STRESS

=> d rank L17

L18 392 L12 AND L13

L19 42 SKIN STRESS

L20 28/60 LAT?

L21 11 L19 AND L20

L22 0 L18 AND L21

L23 0 L18 AND L19

L18 ANSWER 1 OF 392 CAPLUS COPYRIGHT 2003 ACS
AN 2002:510918 CAPLUS

DN 138:180287

TI Modulation of tamoxifen-induced apoptosis by peripheral ***benzodiazepine*** receptor ligands in breast cancer cells

AU Strohmeyer, Renate; Roller, Marc; Sanger, Nicole; Knecht, Rainald; Kuhl, Herbert

CS Department of Gynecology and Obstetrics, Johann Wolfgang Goethe University, Universitätsfrauenklinik, Frankfurt, D-60590, Germany

SO Biochemical Pharmacology (2002), 64(1), 99-107
CODEN: BCPC6; ISSN: 0006-2952

PB Elsevier Science Inc.

DT Journal

LA English

AB The peripheral ***benzodiazepine*** receptor (PBR), an integral protein of the mitochondrial membrane, is involved in the formation of mitochondrial permeability transition (MPT) pores. The opening of the MPT-leading to the dissipation of the inner-mitochondrial transmembrane potential (.DELTA..PSI.m)-is considered to be an early apoptotic event. Therefore, we investigated the effect of the high-affinity PBR ligands Ro5-4864 and PK 11195 on tamoxifen (TAM)-induced apoptosis in MCF-7 and BT-20 breast cancer cell lines. Application of 100 nM TAM led to induction of apoptosis in both cell lines. Estrogen receptor (ER)-pos. MCF-7 cells arrested in G2/M by TAM treatment showed no general dissipation of .DELTA..PSI.m, but redn. of .DELTA..PSI.m was obsd. in a population of cells with high .DELTA..PSI.m. In ER-neg. BT-20 cells TAM treatment induced no arrest of the cell cycle but dissipation of .DELTA..PSI.m. In both cell lines, nanomolar concns. of the PBR ligands, which showed minor pro-apoptotic action themselves, reduced TAM-induced decrease of .DELTA..PSI.m and apoptosis. In MCF-7 cells, a redn. of bc1-2 protein expression by TAM treatment was abolished by a combination of TAM with PBR ligands. Bax protein expression in BT-20 cells showed a significant increase in TAM-treated cells after 24 h but was not increased when treated with TAM and PBR ligands. From these findings, we concluded that binding of PBR ligands in nanomolar concns. protects cells against apoptosis.

RE.CNT 32 THERE ARE 32 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L18 ANSWER 2 OF 392 CAPLUS COPYRIGHT 2003 ACS
AN 2001:667333 CAPLUS

DN 136:79252

TI 2-Arylpyrazolo[1,5-a]pyrimidin-3-yl acetamides. New potent and selective peripheral ***benzodiazepine*** receptor ligands

AU Selleri, S.; Bruni, F.; Costagli, C.; Costanzo, A.; Guerrini, G.; Ciciani, G.; Costa, B.; Martini, C.

CS Dipartimento di Scienze Farmaceutiche, Universita di Firenze, Florence, 50121, Italy

SO Bioorganic & Medicinal Chemistry (2001), 9(10), 2661-2671
CODEN: BMECEP; ISSN: 0968-0896

PB Elsevier Science Ltd.

DT Journal

LA English

AB A new class of N,N-diethyl-(2-arylpyrazolo[1,5-a]pyrimidin-3-yl)acetamides, as azaisosteres of Alpidem, was prep'd. following a novel synthetic method and their affinities for both the peripheral (PBR) and the central (CBR) ***benzodiazepine*** receptors were evaluated. Binding assays were carried out using both [³H]PK 11195 and [³H] ***Ro*** ***5*** - ***4864*** as radioligands for PBR, whereas [³H]Ro 15-1788 was used for CBR, in rat kidney and rat cortex, resp. The tested compds. exhibited a broad range of binding affinities from as low as 0.76 nM to inactivity and most of them proved to be high selective ligands for PBR. The preliminary SAR studies suggested some of the structural features required for high affinity and selectivity; particularly the substituents on the pyrimidine moiety seemed to play an important role in PBR vs. CBR selectivity. A subset of the highest affinity compds. was also tested for their ability to stimulate steroid biosynthesis in C6 glioma rat cells and

some of these were found to increase pregnenolone formation with potency similar to ***Ro*** - ***5*** - ***4864*** and PK 11195.
RE.CNT 60 THERE ARE 60 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L18 ANSWER 3 OF 392 CAPLUS COPYRIGHT 2003 ACS
AN 2001:492993 CAPLUS
DN 136:241286
TI Reduction of acute inflammation in rats by diazepam: role of peripheral ***benzodiazepine*** receptors and corticosterone
AU Lazzarini, Ricardo; Malucelli, Benjamin Eurico; Palermo-Neto, Joao
CS Laboratory of Applied Pharmacology and Toxicology, Department of Pathology, School of Veterinary Medicine, University of Sao Paulo, Sao Paulo, CEP 05508-000, Brazil
SO Immunopharmacology and Immunotoxicology (2001), 23(2), 253-265
CODEN: IITOEI; ISSN: 0892-3973
PB Marcel Dekker, Inc.
DT Journal
LA English
AB This work investigated the possible roles of peripheral-type ***benzodiazepine*** receptors (PBRs) and corticosterone on the anti-inflammatory effects of diazepam. Expts. were conducted to assess the effects of a single dose (10.0 mg/kg) of diazepam on carrageenin-induced paw edema (CIPE), pleurisy and increase in vascular permeability in rats. Diazepam or ***Ro*** - ***5*** - ***4864*** (a PBR agonist) reduced CIPE values; prior treatment with PK 11195 (a nonbenzodiazepine PBR antagonist) suppressed the effects of either diazepam or ***Ro*** - ***5*** - ***4864*** on CIPE; diazepam reduced the vol. of the pleural exudate in carrageenin-injected rats, as well as leukocyte counts; diazepam inhibited the increase in vascular permeability caused by carrageenin; adrenalectomy suppressed the effects of diazepam on CIPE; diazepam treatment increased the serum concn. of corticosterone. These results suggest a relevant role of PBR and corticosterone in diazepam-induced changes in inflammation. The results are discussed in the light of a possible activation of mitochondrial PBRs within the adrenal gland cells by diazepam, thereby increasing serum corticosterone and thus reducing CIPE.

RE.CNT 37 THERE ARE 37 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

49 FILES HAVE ONE OR MORE ANSWERS,
L25 QUE BENZODIAZEPINE (5N) DIAZEPAM OR RO 5-4864

43 FILES HAVE ONE OR MORE ANSWERS,
L26 QUE TREAT (5N) (SKIN STRESS OR SUN BURN OR SKIN ITCH OR PSORIASIS)

0 FILES HAVE ONE OR MORE ANSWERS
L27 QUE L25 AND NOCARDIA

8 FILES HAVE ONE OR MORE ANSWERS
L28 QUE L25 AND STREPTOMYCES

0 FILES HAVE ONE OR MORE ANSWERS
L29 QUE L25 AND L26

0 FILES HAVE ONE OR MORE ANSWERS
L30 QUE L28 AND L26

0 FILES HAVE ONE OR MORE ANSWERS,
L31 QUE L25 AND L26

INDEX 'ADP' 'ADPINSIGHT', ADISNEWS, AGRICOLA, A T QUASCI, BIOPARTNERS, BIOPARTNERS, BIOSIS, BIOTECHABS, BIOTECHDS, BIOTECHNO, CABA, CANCERLIT, CAPLUS, CEABA-VTB, CEN, CIN, CONFSCI, CROPB, CROPU, DDFB, DDFU, DGENE, DRUGB, DRUGLAUNCH, DRUGMONOG2, ...' ENTERED AT 11:32:48 ON 18 APR 2003

53 FILES HAVE ONE OR MORE ANSWERS

L1 QUE (DERTMATOSIS OR ((SKIN OR CUTANEOUS OR DERMATOLOGICAL OR EPIDERMAL OR EPIDERM OR CUTANEUM) (5N) STRESS))

63 FILES HAVE ONE OR MORE ANSWERS

L2 QUE NOBRIUM OR BENZODIAZEPINE

60 FILES HAVE ONE OR MORE ANSWERS

L3 QUE (SKIN OR CUTANEOUS OR DERMATOLOGICAL OR EPIDERMAL OR EPIDERM OR CUTANEUM) (5N) SOLAR ERYTHEMOR SUNBURN OR WRINKLES OR FREE-RADICAL INHIBIT?

65 FILES HAVE ONE OR MORE ANSWERS

L4 QUE TREAT OR CURE OR INHIBIT OR REDUCE

65 FILES HAVE ONE OR MORE ANSWERS

L5 QUE TOPICAL (5N) COMPOSITION OR PREPARATION OR PHARMACEUTICAL

51 FILES HAVE ONE OR MORE ANSWERS

L6 QUE L2 AND L5

16 FILES HAVE ONE OR MORE ANSWERS

L7 QUE (L1 AND L3) AND L4

3 FILES HAVE ONE OR MORE ANSWERS

L8 QUE L6 AND L7

=> d rank

F1 1 USPATFULL

F2 1 WPIDS

F3 1 WPINDEX

=> file f1-f3

FILE 'WPINDEX' ACCESS NOT AUTHORIZED

L9 2 L8

=> dup rem L9

PROCESSING COMPLETED FOR L9

L10 2 DUP REM L9 (0 DUPLICATES REMOVED)

=> d bib, abs L9 1-2

L9 ANSWER 1 OF 2 USPATFULL

AN 2003:92727 USPATFULL

TI Cosmetic or dermatological composition comprising a combination of an elastase inhibitor of the N-acylaminoamide family and at least one myorelaxing agent

IN Breton, Lionel, Versailles, FRANCE

PA L'OREAL, Paris, FRANCE (non-U.S. corporation)

PT US 2003064085 A1 20030403

AI US 2002-179984 A1 20020626 (10)

PRAI FR 2001-8436 20010626

DT Utility

FS APPLICATION

LREP OBLON SPIVAK MCCLELLAND MAIER & NEUSTADT PC, FOURTH FLOOR, 1755 JEFFERSON DAVIS HIGHWAY, ARLINGTON, VA, 22202

CLMN Number of Claims: 21

ECL Exemplary Claim: 1

DRWN No Drawings

LN.CNT 1242

AB Cosmetic or dermatological composition characterized in that it comprises a combination of an elastase inhibitor of the N-acylaminoamide family and at least one myorelaxing agent.

L9 ANSWER 2 OF 2 WPIDS (C) 2003 THOMSON DERWENT

AN 2000-378535 [33] WPIDS

DNC C2000-114758

TI Use of peripheral ***benzodiazepine*** receptor ligands to prepare ***topical*** cosmetic, pharmaceutical or ***dermatological*** ***compositions*** for treating ***cutaneous*** ***stress*** , e.g. ***sunburn*** or ***skin*** aging.

DC B02 D16 D21

IN CASELLAS, P; DEROCQ, J M; DEROCQ, J

PA (SNFI) SANOFI SA; (SNFI) SANOFI-SYNTHELABO

CYC 91
PI FR 2785803 A1 20000519 (200033)* 18p
WO 2000028947 A2 20000525 (200033) FR
RW: AT BE CH CY DE DK EA ES FI FR GB GH GM GR IE IT KE LS LU MC MW NL
OA PT SD SE SL SZ TZ UG ZW
W: AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES
FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS
LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL
TJ TM TR TT TZ UA UG US VN YU ZA ZW
AU 2000011661 A 20000605 (200042)
EP 1131039 A2 20010912 (200155) FR
R: AL AT BE CH CY DE DK ES FI FR GB GR IE IT LI LT LU LV MC MK NL PT
RO SE SI
KR 2001089475 A 20011006 (200220)
HU 2001005058 A2 20020528 (200249)
JP 2002529486 W 20020910 (200274) 32p
ADT FR 2785803 A1 FR 1998-14387 19981117; WO 2000028947 A2 WO 1999-FR2761
19991110; AU 2000011661 A AU 2000-11661 19991110; EP 1131039 A2 EP
1999-972094 19991110, WO 1999-FR2761 19991110; KR 2001089475 A KR
2001-706238 20010517; HU 2001005058 A2 WO 1999-FR2761 19991110, HU
2001-5058 19991110; JP 2002529486 W WO 1999-FR2761 19991110, JP
2000-581995 19991110
FDT AU 2000011661 A Based on WO 200028947; EP 1131039 A2 Based on WO
200028947; HU 2001005058 A2 Based on WO 200028947; JP 2002529486 W Based
on WO 200028947
PRAI FR 1998-14387 19981117
AN 2000-378535 [33] WPIDS
AB FR 2785803 A UPAB: 20000712
NOVELTY - Peripheral ***benzodiazepine*** receptor (PBR) ligands are
used to prepare ***topical*** cosmetic, pharmaceutical or
dermatological ***compositions*** for treating
cutaneous ***stress***.
DETAILED DESCRIPTION - INDEPENDENT CLAIMS are also included for:
(1) use of PBR ligands to prepare ***topical*** cosmetic and/or
dermatological ***compositions*** for reducing ***wrinkles***,
reducing ***sunburn*** or protecting against free radicals;
(2) a ***topical*** cosmetic and/or dermatological
composition containing a PBR ligand.
ACTIVITY - Dermatological; antiinflammatory; antipruritic;
antipsoriatic; immunomodulatory. An experiment to determine the
photoprotective effect of PBR ligands against ultraviolet-induced erythema
and edema on guinea pigs is described but no results are given.
MECHANISM OF ACTION - PBR agonist.
USE - The PBR ligands are useful for treating ***cutaneous***
stress, e.g. ***skin*** irritation, erythema, pruritis, skin
aging, psoriasis, herpes, dermatitis, lichen, insect bites, fibrosis,
immunological disorders or eczema.
Dwg.0/7